Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -12.62%75.04B | -10.42%50.52B | -2.19%23.77B | 3.79%105.62B | 17.93%85.87B | 17.26%56.4B | 8.16%24.3B | -6.89%101.76B | -9.79%72.82B | -12.85%48.1B |
| Operating income | -12.62%75.04B | -10.42%50.52B | -2.19%23.77B | 3.79%105.62B | 17.93%85.87B | 17.26%56.4B | 8.16%24.3B | -6.89%101.76B | -9.79%72.82B | -12.85%48.1B |
| Operating expenses | 13.39%-70.75B | 11.35%-47.42B | 2.85%-22.39B | -4.29%-100.08B | -19.39%-81.69B | -18.65%-53.49B | -10.13%-23.05B | 7.02%-95.96B | 9.52%-68.42B | 12.95%-45.08B |
| Gross profit | 2.36%4.29B | 6.71%3.1B | 10.05%1.38B | -4.55%5.54B | -4.74%4.19B | -3.60%2.91B | -18.57%1.25B | -4.74%5.81B | -13.83%4.4B | -11.34%3.02B |
| Selling expenses | -2.04%-733.97M | -1.84%-495.28M | 10.93%-223.52M | 7.03%-1B | 6.12%-719.33M | 6.05%-486.35M | -4.51%-250.95M | -0.86%-1.08B | 3.91%-766.25M | 2.86%-517.65M |
| Administrative expenses | 2.21%-2.25B | -0.04%-1.5B | -2.37%-711.3M | 1.61%-3.33B | 3.61%-2.3B | 5.78%-1.5B | 5.00%-694.81M | 0.31%-3.38B | 2.74%-2.38B | -0.48%-1.6B |
| Research and development expenses | 37.06%-78.26M | 45.50%-42.12M | 21.12%-20.9M | 48.26%-120.66M | 12.71%-124.34M | -198.70%-77.29M | 8.95%-26.49M | -18.89%-233.19M | -34.05%-142.45M | 47.10%-25.88M |
| Profit from asset sales | -76.39%9.76M | -51.00%5.91M | 157.21%487.39K | -63.26%68.43M | -71.99%41.36M | -80.54%12.07M | -258.56%-851.87K | -4.92%186.27M | 1,529.95%147.64M | 847.37%61.99M |
| Revaluation surplus | -69.60%11.66M | 157.69%7.36M | 103.98%595.4K | -8.36%244.56M | 177.02%38.34M | 53.24%-12.76M | -81.27%-14.95M | 354.32%266.88M | 46.78%-49.77M | 64.93%-27.29M |
| -Changes in the fair value of other assets | -69.60%11.66M | 157.69%7.36M | 103.98%595.4K | -8.36%244.56M | 177.02%38.34M | 53.24%-12.76M | -81.27%-14.95M | 354.32%266.88M | 46.78%-49.77M | 64.93%-27.29M |
| Impairment and provision | -27.86%-145.04M | -18.66%-118.79M | -19.66%-60.54M | 68.51%-110.81M | -32.84%-113.44M | -116.88%-100.11M | -31.24%-50.59M | -144.36%-351.89M | 1.18%-85.4M | 18.76%-46.16M |
| -Other impairment is provision | -27.86%-145.04M | -18.66%-118.79M | -19.66%-60.54M | 68.51%-110.81M | -32.84%-113.44M | -116.88%-100.11M | -31.24%-50.59M | -144.36%-351.89M | 1.18%-85.4M | 18.76%-46.16M |
| Special items of operating profit | -5.13%2.89B | -5.89%1.87B | -36.97%602.54M | -11.71%4.22B | -9.03%3.05B | -7.14%1.98B | 1.24%955.9M | 17.49%4.78B | 12.25%3.35B | 6.94%2.14B |
| Adjustment items of operating profit | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0.01 | ---- |
| Operating profit | -2.08%3.75B | 3.33%2.66B | -19.50%886.48M | -9.36%5.19B | -10.40%3.83B | -10.72%2.57B | -19.77%1.1B | 10.11%5.72B | -2.24%4.28B | -3.05%2.88B |
| Financing cost | 38.04%-154.43M | 52.19%-60.51M | 76.44%-19.92M | 4.52%-247.16M | -31.30%-249.25M | -215.82%-126.57M | 46.93%-84.56M | -613.34%-258.86M | -232.39%-189.83M | -184.24%-40.08M |
| Adjustment items of earning before tax | -87.02%8.02M | -71.39%15.77M | 1,403.31%39.25M | 111.88%78.04M | 118.17%61.78M | 231.18%55.11M | -81.76%2.61M | 929.51%36.83M | 142.67%28.32M | 213.79%16.64M |
| Earning before tax | -1.06%3.6B | 4.49%2.61B | -11.13%905.81M | -8.78%5.02B | -11.44%3.64B | -12.49%2.5B | -16.96%1.02B | 4.91%5.5B | -9.15%4.11B | -4.89%2.85B |
| Tax | -14.39%-692.83M | -17.34%-485.62M | -6.82%-187.88M | 20.56%-838.2M | 26.67%-605.65M | 23.38%-413.84M | 22.89%-175.87M | -9.05%-1.06B | -9.17%-825.92M | 2.37%-540.14M |
| After-tax profit from continuing operations | -4.14%2.91B | 1.94%2.12B | -14.87%717.93M | -5.98%4.18B | -7.62%3.04B | -9.95%2.08B | -15.61%843.39M | 3.97%4.45B | -12.83%3.29B | -5.47%2.31B |
| Earning after tax | -4.14%2.91B | 1.94%2.12B | -14.87%717.93M | -5.98%4.18B | -7.62%3.04B | -9.95%2.08B | -15.61%843.39M | 3.97%4.45B | -12.83%3.29B | -5.47%2.31B |
| Minority profit | 9.44%232.34M | 27.98%178.01M | 84.36%72.94M | 13.49%262M | 58.14%212.3M | 7.88%139.1M | -8.48%39.56M | 17.33%230.85M | -31.10%134.25M | 7.10%128.94M |
| Profit attributable to shareholders | -5.17%2.68B | 0.08%1.95B | -19.76%644.99M | -7.05%3.92B | -10.41%2.83B | -11.00%1.95B | -15.93%803.82M | 3.32%4.21B | -11.83%3.15B | -6.11%2.19B |
| Basic earnings per share | -5.32%0.3684 | 0.97%0.2707 | -18.18%0.09 | -7.24%0.5396 | -9.53%0.3891 | -11.14%0.2681 | -15.38%0.11 | 4.83%0.5817 | -11.01%0.4301 | -2.68%0.3017 |
| Diluted earnings per share | -5.20%0.3681 | 1.08%0.2704 | -18.18%0.09 | -7.33%0.5386 | -9.72%0.3883 | -11.34%0.2675 | -15.38%0.11 | 4.74%0.5812 | -11.01%0.4301 | -2.68%0.3017 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | Shinaga Zhonghe Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- | -- | Shinaga Zhonghe Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.